Organogenesis (ORGO) News Today $3.05 -0.06 (-1.93%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Organogenesis files to sell 130K shares of common stock for holdersDecember 20 at 6:53 AM | markets.businessinsider.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells $19,491.65 in StockDecember 17, 2024 | insidertrades.comGary S. Gillheeney Sells 5,585 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) StockOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) CEO Gary S. Gillheeney sold 5,585 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.49, for a total transaction of $19,491.65. Following the completion of the transaction, the chief executive officer now owns 3,039,194 shares of the company's stock, valued at $10,606,787.06. This trade represents a 0.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.December 16, 2024 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 55,615 SharesOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) CEO Gary S. Gillheeney sold 55,615 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total transaction of $186,866.40. Following the completion of the sale, the chief executive officer now owns 3,044,779 shares of the company's stock, valued at approximately $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.December 16, 2024 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney Sells 157,448 SharesDecember 13, 2024 | insidertrades.comInsider Selling: Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Sells 18,416 Shares of StockDecember 10, 2024 | insidertrades.comJacobs Levy Equity Management Inc. Sells 148,326 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)Jacobs Levy Equity Management Inc. decreased its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 34.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 281,478 shares of the company's stoDecember 10, 2024 | marketbeat.comAdvantage Alpha Capital Partners LP Trims Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)Advantage Alpha Capital Partners LP lessened its position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 71.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 101,558 shares of the company's stock after selling 256November 27, 2024 | marketbeat.comOrganogenesis Expands Manufacturing Capacity to Support Future GrowthNovember 22, 2024 | globenewswire.comAnalysts Set Expectations for Organogenesis FY2024 EarningsOrganogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for Organogenesis in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings per share of (November 18, 2024 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Organogenesis Holdings (ORGO)November 15, 2024 | markets.businessinsider.comOrganogenesis ‘commends’ final local coverage determinationsNovember 15, 2024 | markets.businessinsider.comOrganogenesis (NASDAQ:ORGO) Announces Earnings Results, Beats Estimates By $0.11 EPSOrganogenesis (NASDAQ:ORGO - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. The company had revenue of $115.18 million during the quarter, compared to analysts' expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the previous year, the business earned $0.02 earnings per share.November 15, 2024 | marketbeat.comOrganogenesis Commends Final LCDsNovember 15, 2024 | globenewswire.comOrganogenesis Reports Robust Third Quarter GrowthNovember 14, 2024 | markets.businessinsider.comOrganogenesis (NASDAQ:ORGO) Shares Gap Down - Here's What HappenedOrganogenesis (NASDAQ:ORGO) Shares Gap Down - Here's WhyNovember 14, 2024 | marketbeat.comOrganogenesis Holdings Secures $130M Investment for GrowthNovember 14, 2024 | markets.businessinsider.comOrganogenesis Holdings Inc. Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comOrganogenesis Holdings Inc (ORGO) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 13, 2024 | finance.yahoo.comOrganogenesis (ORGO) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | fool.comOrganogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comOrganogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred StockNovember 12, 2024 | globenewswire.comOrganogenesis Holdings Inc.: Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee OsteoarthritisNovember 12, 2024 | finanznachrichten.deOrganogenesis provides update on Phase 3 trial of ReNu in knee osteoarthritisNovember 12, 2024 | markets.businessinsider.comOrganogenesis Holdings (ORGO) Receives a Buy from Lake StreetNovember 12, 2024 | markets.businessinsider.comOrganogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee OsteoarthritisNovember 11, 2024 | globenewswire.comOrganogenesis (ORGO) Set to Announce Quarterly Earnings on TuesdayOrganogenesis (NASDAQ:ORGO) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636063)November 5, 2024 | marketbeat.comOrganogenesis Holdings And 2 Other US Penny Stocks To WatchNovember 4, 2024 | uk.finance.yahoo.comMass. company offered millions to manufacture artificial skin in the Ocean StateOctober 31, 2024 | bizjournals.comBoston biotech aims to put some skin in the RI life sciences gameOctober 31, 2024 | bizjournals.comShareholders in Organogenesis Holdings (NASDAQ:ORGO) are in the red if they invested three years agoOctober 30, 2024 | finance.yahoo.comAssenagon Asset Management S.A. Has $5.48 Million Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)Assenagon Asset Management S.A. cut its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 51.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,915,729 shares of the company'October 30, 2024 | marketbeat.comOrganogenesis Hldgs (NASDAQ:ORGO) Stock, Option ChainOctober 24, 2024 | benzinga.comOrganogenesis Hldgs (NASDAQ:ORGO) Stock, Short Interest ReportOctober 23, 2024 | benzinga.comOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024October 16, 2024 | globenewswire.comOrganogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain StockOctober 15, 2024 | msn.comOrganogenesis: Lurking Disruption With Recovery To FollowOctober 14, 2024 | seekingalpha.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Expected to Earn FY2024 Earnings of ($0.17) Per ShareOrganogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of Organogenesis in a report issued on Wednesday, October 9th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings pOctober 11, 2024 | marketbeat.comDimensional Fund Advisors LP Buys 333,123 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)Dimensional Fund Advisors LP raised its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 19.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,036,743 shares of the company's stock after purchasing an additional 333,123 sharesOctober 9, 2024 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Shares Purchased by AQR Capital Management LLCAQR Capital Management LLC raised its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 76.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,268,760 shares of the company's stock after buying an additional 986,132 shOctober 4, 2024 | marketbeat.comOrganogenesis Holdings (ORGO) Receives a Buy from Cantor FitzgeraldOctober 3, 2024 | markets.businessinsider.comOrganogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot UlcersOctober 1, 2024 | globenewswire.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Down 16.5% in SeptemberOrganogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 11,680,000 shares, a drop of 16.5% from the August 31st total of 13,990,000 shares. Based on an average daily trading volume, of 723,500 shares, the days-to-cover ratio is presently 16.1 days. Approximately 15.0% of the company's stock are short sold.September 28, 2024 | marketbeat.comOrganogenesis Holdings Inc. (NASDAQ:ORGO) Shares Acquired by Wealth Dimensions Group Ltd.Wealth Dimensions Group Ltd. increased its position in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 435.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 407,965 shares of the company'September 16, 2024 | marketbeat.comOrganogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in SeptemberSeptember 4, 2024 | globenewswire.comAssenagon Asset Management S.A. Has $11.14 Million Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)Assenagon Asset Management S.A. grew its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 309.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,977,124 shares of the companyAugust 17, 2024 | marketbeat.comVanguard Group Inc. Sells 1,825,428 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)Vanguard Group Inc. lowered its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 34.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,535,299 shares of the company's stock after selling 1,August 15, 2024 | marketbeat.comOrganogenesis Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 12, 2024 | finance.yahoo.comOrganogenesis Holdings Inc. Reports Second Quarter 2024 Financial ResultsAugust 9, 2024 | markets.businessinsider.comOrganogenesis (ORGO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.com Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You See Trump’s Bombshell Exec. Order 001? (Ad)Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. ORGO Media Mentions By Week ORGO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORGO News Sentiment▼0.510.60▲Average Medical News Sentiment ORGO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORGO Articles This Week▼62▲ORGO Articles Average Week Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Harmony Biosciences News Galapagos News Xencor News Evotec News Arcutis Biotherapeutics News Nurix Therapeutics News Arcus Biosciences News Kiniksa Pharmaceuticals News Immunocore News Ocular Therapeutix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORGO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts